Brad Kahl, MD
Fisher RI et al. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 2006;24(30):4867-74. Abstract
Goy A et al. Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: Phase II MCL-001 (EMERGE) study. J Clin Oncol 2013;31(29):3688-95. Abstract
Goy A et al. Bortezomib in patients with relapsed or refractory mantle cell lymphoma: Updated time-to-event analyses of the multicenter phase 2 PINNACLE study. Ann Oncol 2009;20(3):520-5. Abstract
Hess G et al. Phase III study to evaluate temsirolimus compared with investigator’s choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol 2009;27(23):3822-9. Abstract
Wang ML et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med 2013;369(6):507-16. Abstract
Wang M et al. Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: A phase 1/2 clinical trial. Lancet Oncol 2012;13(7):716-23. Abstract
Mitchell R Smith, MD, PhD
Anderson DR et al. Targeted anti-cancer therapy using rituximab, a chimaeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin’s B-cell lymphoma. Biochem Soc Trans 1997;25(2):705-8. Abstract
Brown JR et al. Safety and efficacy of obinutuzumab (GA101) with fludarabine/cyclophosphamide (G-FC) or bendamustine (G-B) in the initial therapy of patients with chronic lymphocytic leukemia (CLL): Results from the phase 1b Galton trial (GAO4779g). Proc ASH 2013;Abstract 523.
Byrd JC et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 2013;369(1):32-42. Abstract
Cartron G et al. Results from a phase II study of obinutuzumab (GA101) monotherapy in relapsed/refractory chronic lymphocytic leukemia (CLL). EHA 2011;Abstract 101.
Certo M et al. Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell 2006;9(5):351-65. Abstract
Chen L et al. Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell 2005;17(3):393-403. Abstract
Clynes RA et al. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med 2000;6(4):443-6. Abstract
Cragg MS. CD20 antibodies: Doing the time warp. Blood 2011;118(2):219-20. Abstract
Fischer K et al. Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: A multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 2012;30(26):3209-16. Abstract
Goede V et al. Head-to-head comparison of obinutuzumab (GA101) plus chlorambucil (Clb) versus rituximab plus Clb in patients with chronic lymphocytic leukemia (CLL) and co-existing medical conditions (comorbidities): Final stage 2 results of the CLL11 trial. Proc ASH 2013;Abstract 6.
Golay J et al. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood 2000;95(12):3900-8. Abstract
Hallek M et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: A randomised, open-label, phase 3 trial. Lancet 2010;376(9747):1164-74. Abstract
Hillmen P et al. Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol 2007;25(35):5616-23. Abstract
Kim H et al. Hierarchical regulation of mitochondrion-dependent apoptosis by BCL-2 subfamilies. Nat Cell Biol 2006;8(12):1348-58. Abstract
Lannutti BJ et al. CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood 2011;117(2):591-4. Abstract
Morschhauser F et al. Phase I study of RO5072759 (GA101) in relapsed/refractory chronic lymphocytic leukemia. Proc ASH 2009;Abstract 884.
Reff ME et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994;83(2):435-45. Abstract
Shan D et al. Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells. Cancer Immunol Immunother 2000;48(12):673-83. Abstract
Silverman GJ, Weisman S. Rituximab therapy and autoimmune disorders: Prospects for anti-B cell therapy. Arthritis Rheum 2003;48(6):1484-92. Abstract
Tse C et al. ABT-263: A potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res 2008;68(9):3421-8. Abstract
Willis SN et al. Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak. Science 2007;315(5813):856-9. Abstract
Steven M Horwitz, MD
A randomized phase III study to evaluate the efficacy of chemoimmunotherapy with the monoclonal antibody campath-1H (alemtuzumab) given in combination with 2-weekly CHOP versus 2-weekly CHOP alone and consolidated by autologous stem cell transplant, in young patients with previously untreated systemic peripheral T-cell lymphomas. NCT00646854
Campuzano-Zuluaga G et al. Frequency and extent of CD30 expression in diffuse large B-cell lymphoma and its relation to clinical and biologic factors: A retrospective study of 167 cases. Leuk Lymphoma 2013;54(11):2405-11. Abstract
Coiffier B et al. Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. J Clin Oncol 2012;30(6):631-6. Abstract
Coiffier B et al. Romidepsin induces durable responses in patients with peripheral T-cell lymphoma: GPI-06–0002 study update. Blood 2012;Abstract 3641.
ECHELON-2: A comparison of brentuximab vedotin and CHP with standard-of-care CHOP in the treatment of patients with CD30-positive mature T-cell lymphomas. NCT01777152
Fanale MA et al. Brentuximab vedotin administered concurrently with multi-agent chemotherapy as frontline treatment of ALCL and other CD30-positive mature T-cell and NK-cell lymphomas. Proc ASH 2012;Abstract 60.
Friedberg J et al. Phase 2 trial of alisertib (MLN8237), an investigational, potent inhibitor of aurora A kinase (AAK), in patients (pts) with aggressive B- and T-cell non-Hodgkin lymphoma (NHL). Proc ASH 2011;Abstract 95.
Gardner LJ et al. CD30 expression in follicular lymphoma. Arch Pathol Lab Med 2001;125(8):1036-41. Abstract
Hu et al. CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: A report from the International DLBCL Rituximab-CHOP Consortium Program Study. Blood 2013;121(14), 2715-24. Abstract
Jacobsen E. A phase 2 study of brentuximab vedotin in patients with relapsed or refractory CD30-positive non-Hodgkin lymphomas: Interim results. Proc ASH 2012;Abstract 2746.
Horwitz S et al. Belinostat in relapsed or refractory peripheral T-cell lymphoma (R/R PTCL) subtype angioimmunoblastic T-cell lymphoma (AITL): Results from the pivotal BELIEF trial. Proc ICML 2013;Abstract 153.
Horwitz S et al. Preliminary safety and efficacy of IPI-145, a potent inhibitor of phosphoinositide-3-kinase-δ,γ, in patients with relapsed/refractory lymphoma. Proc ASCO 2013;Abstract 8518.
Krathen M et al. Brentuximab vedotin demonstrates significant clinical activity in relapsed or refractory mycosis fungoides with variable CD30 expression. Proc ASH 2012;Abstract 797.
O’Connor OA et al. Belinostat, a novel pan-histone deacetylase inhibitor in relapsed or refractory peripheral T-cell lymphoma: Results from the BELIEF trial. Proc ASCO 2013;Abstract 8507.
O’Connor OA et al. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: Results from the pivotal PROPEL study. J Clin Oncol 2011;29(9):1182-9. Abstract
Phase 3 multi-center randomized study to compare efficacy and safety of romidepsin CHOP (Ro-CHOP) versus CHOP in patients with previously untreated peripheral T-cell lymphoma. NCT01796002
Pro B et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: Results of a phase II study. J Clin Oncol 2012;30(18):2190-6. Abstract
Sabattini E et al. CD30 expression in peripheral T-cell lymphomas. Haematologica 2013;98(8):e81-e82. Abstract
Study of pralatrexate versus observation following CHOP-based chemotherapy in previously undiagnosed peripheral T-cell lymphoma patients. NCT01420679
Taylor CR, Levenson RM. Quantification of immunohistochemistry — Issues concerning methods, utility and semiquantitative assessment II. Histopathology 2006;49(4):411-24. Abstract
Went P et al. Marker expression in peripheral T-cell lymphoma: A proposed clinical-pathologic prognostic score. J Clin Oncol 2006;24(16):2472-9. Abstract
Michele E Ghielmini, MD, PhD
Ardeshna KM et al. An Intergroup randomised trial of rituximab versus a watch and wait strategy in patients with Stage II, III, IV, asymptomatic, non-bulky follicular lymphoma (Grades 1, 2 and 3a). A preliminary analysis. Proc ASH 2010;Abstract 6.
Burke JM et al. Differences in quality of life between bendamustine plus rituximab compared with standard first-line treatments in patients with previously untreated advanced indolent non-Hodgkin’s lymphoma or mantle cell lymphoma. Proc ASH 2012;Abstract 155.
Chiappella A et al. Rituximab-CHOP21 plus lenalidomide is effective and feasible in elderly untreated diffuse large B-cell lymphoma: Results of phase II REAL07 study of the Fondazione Italiana Linfomi (FIL). Proc ASH 2012;Abstract 903.
Flinn IW et al. An open-label, randomized study of bendamustine and rituximab (BR) compared with rituximab, cyclophosphamide, vincristine, and prednisone (R-CVP) or rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in first-line treatment of patients with advanced indolent non-Hodgkin’s lymphoma (NHL) or mantle cell lymphoma (MCL): The Bright study. Proc ASH 2012;Abstract 902.
Ghielmini M et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. Blood 2004;103(12):4416-23. Abstract
Kahl BS et al. Results of Eastern Cooperative Oncology Group Protocol E4402 (RESORT): A randomized phase III study comparing two different rituximab dosing strategies for low tumor burden follicular lymphoma. Proc ASH 2011;Abstract LBA-6.
Kotla V et al. Mechanism of action of lenalidomide in hematological malignancies. J Hematol Oncol 2009;2:36. Abstract
Kridel R et al. Pathogenesis of follicular lymphoma. J Clin Invest 2012;122(10):3424-31. Abstract
Nowakowski GS et al. Combination of lenalidomide with R-CHOP is well tolerated and effective as initial therapy for aggressive B-cell lymphomas — A phase II study. Proc ASH 2012;Abstract 689.
Rummel MJ et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: An open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 2013;381(9873):1203-10. Abstract
Laurie H Sehn, MD, MPH
Akyurek N et al. Prognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab. Cancer 2012;118(17):4173-83. Abstract
Barrans S et al. Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab. J Clin Oncol 2010;28(20):3360-5. Abstract
Cunningham D et al. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: A phase 3 comparison of dose intensification with 14-day versus 21-day cycles. Lancet 2013;381(9880):1817-26. Abstract
Green TM et al. Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol 2012;30(28):3460-7. Abstract
Habermann TM et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006;24(19):3121-7. Abstract
Hernandez-Ilizaliurri FJ et al. Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype. Cancer 2011;117(22):5058-66. Abstract
Hitz F et al. Outcome of patients with chemotherapy refractory and early progressive diffuse large B cell lymphoma after R-CHOP treatment. Blood 2010;Abstract 1751.
Horn H et al. MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma. Blood 2012;121(12):2253-63. Abstract
Hu S et al. CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: A report from the International DLBCL Rituximab-CHOP Consortium Program Study. Blood 2013;121(14), 2715-24. Abstract
Jaeger U et al. Rituximab maintenance treatment versus observation in patients with aggressive B-cell lymphoma: Results of the AGMT NHL13 trial. Proc ICML 2013;Abstract 119.
Johnson NA et al. Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol 2012;30(28):3452-9. Abstract
Kojima M et al. MYC rearrangements are useful for predicting outcomes following rituximab and chemotherapy: Multicenter analysis of Japanese patients with diffuse large B-cell lymphoma. Leuk Lymphoma 2013;54(10):2149-54. Abstract
Lenz H et al. Stromal gene signatures in large-B-cell lymphomas. New Engl J Med 2008;359(22):2313-23. Abstract
Meyer PN et al. Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab. J Clin Oncol 2011;29(2):200-7. Abstract
Morrison VA et al. Maintenance rituximab (MR) compared to observation (OBS) after R-CHOP or CHOP in older patients (pts) with diffuse large B-cell lymphoma (DLBCL): An Intergroup E4494/C9793 update. Proc ASCO 2007. No abstract available
Obermann EC et al. Aberrations of the MYC gene in unselected cases of diffuse large B-cell lymphoma are rare and unpredictable by morphological or immunohistochemical assessment. J Clin Pathol 2009;62(8):754-6. Abstract
Savage KJ et al. MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. Blood 2009;114(17):3533-7. Abstract
Shaffer AL et al. Pathogenesis of human B cell lymphomas. Annu Rev Immunol 2012;30:565-610. Abstract
Stiff PJ et al. Autologous transplantation as consolidation for aggressive non-Hodgkin's lymphoma. N Engl J Med 2013;369(18):1681-90. Abstract
Sun H et al. Outcome of patients with double-hit lymphomas treated with CODOX-M/IVAC + R followed by hematopoietic stem cell transplantation in British Columbia. Proc ASH 2013;Abstract 1788.
Visco C et al. Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: A report from the International DLBCL Rituximab-CHOP Consortium Program Study. Leukemia 2012;26(9):2103-13. Abstract
Wright G et al. A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci 2003;100(17):9991-6. Abstract
Ziepert M et al. Standard international prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era. J Clin Oncol 2010;28(14):2373-80. Abstract